(Q44557371)

4 December 2017

title

Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with multiple sclerosis (English)

1 reference

4 December 2017

0 references

Wiesemann E

1

1 reference

4 December 2017

Klatt J

2

1 reference

4 December 2017

Wenzel C

3

1 reference

4 December 2017

Heidenreich F

4

1 reference

4 December 2017

Windhagen A

5

1 reference

4 December 2017

publication date

1 September 2003

1 reference

Clinical and Experimental Immunology

4 December 2017

published in

1 reference

4 December 2017

volume

133

1 reference

4 December 2017

issue

3

1 reference

4 December 2017

page(s)

454-460

1 reference

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02238.X

Mechanisms of action of glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02238.X

Immunogenic potentials of copolymer I in normal human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02238.X

Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02238.X

Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02238.X

Glatiramer acetate (GA) induces IL-13/IL-5 secretion in naive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02238.X

Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02238.X

Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02238.X

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02238.X

Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02238.X

Coordinate regulation of the IL-4, IL-13, and IL-5 cytokine cluster in Th2 clones revealed by allelic expression patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02238.X

IL-4 induces characteristic Th2 responses even in the combined absence of IL-5, IL-9, and IL-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02238.X

Interleukins-4, -5, and -13: emerging therapeutic targets in allergic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02238.X

Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02238.X

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02238.X

Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis. A pilot study

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808789

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

27 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808789

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

27 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808789

The role of IL-13 and its receptor in allergy and inflammatory responses.

27 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808789

Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients

27 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808789

The role of IFN-gamma in the production of Th2 subpopulations: implications for variable Th2-mediated pathologies in autoimmunity

3 November 2018

1 reference

12 December 2020

Selective loss of the suppressor-inducer T-cell subset in progressive multiple sclerosis. Analysis with anti-2H4 monoclonal antibody

1 reference

12 December 2020

Decrease of suppressor inducer (CD4+2H4+) T cells in multiple sclerosis cerebrospinal fluid

1 reference

12 December 2020

T cell subsets in multiple sclerosis: a serial study

1 reference

12 December 2020

Cytokine secretion of myelin basic protein reactive T cells in patients with multiple sclerosis

1 reference

12 December 2020

Mechanisms of immunomodulation by glatiramer acetate

1 reference

12 December 2020

10.1046/J.1365-2249.2003.02238.X

Identifiers

DOI

1 reference

4 December 2017

0 references

1 reference